Search results: Sage Journals

Open accessResearch articleFirst published April, 2024

Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to <12 years,using matching placebo tablets: A randomized study

Sandy Van Hemelryck, Erika Van Landuyt, Veerle Hufkens [...]

Antiviral Therapy

Open accessResearch articleFirst published 2026

Polytherapy and Potential Drug–Drug Interactions in Geriatric Patients of a Tertiary-care Hospital

Shivangi Shukla, Jiya Thosar, Supriya Malhotra [...]

Apollo Medicine

Restricted accessResearch articleFirst published January, 2015

The Wider Use of Fixed-Dose Combinations Emphasizes the Need for a Global Approach to Regulatory Guideline Development

Yvonne Gautam, Ole J. Bjerrum, Merete Schmiegelow

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published July, 2015

An Analysis of the Fixed-Dose Combinations Authorized by the European Union,2009-2014

Dominik Sawicki-Wrzask, Mikael Thomsen, Ole J. Bjerrum

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 2017

Analysis of Fixed-Dose Combination Products Approved by the US Food and Drug Administration,2010-2015

Kyu Chan Kwon, Chulung Lee

Therapeutic Innovation & Regulatory Science

Open accessResearch articleFirst published June, 2025

Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1

Sandy Van Hemelryck, Erika Van Landuyt, Sofie Deleu [...]

Antiviral Therapy

Restricted accessResearch articleFirst published 2019

Investigation of Approval Trends and Benefits of New Fixed-Dose Combination Drugs in Japan

Chikara Kikuchi, Mifuyu Ohno, Takafumi Izumo [...]

Therapeutic Innovation & Regulatory Science

Restricted accessCase reportFirst published January, 2013

Inadequate Therapeutic Response to a Recommended Antituberculosis Fixed-Dose Combination Regimen in an Overweight Patient with Mycobacterium bovis Infection

Célia Lloret-Linares, Stéphane Mouly, Dan-Tranh Hoang-Nguyen [...]

Annals of Pharmacotherapy

Free accessResearch articleFirst published July, 2015

A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents

Heather Sevinsky, Xiaolu Tao, Reena Wang [...]

Antiviral Therapy

Open accessReview articleFirst published 2018

Sofosbuvir,velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

Marc Bourlière, Olivia Pietri, Paul Castellani [...]

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published April, 2024

Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to <12 years,using matching placebo tablets: A randomized study

Sandy Van Hemelryck, Erika Van Landuyt, Veerle Hufkens [...]

Antiviral Therapy

Open accessResearch articleFirst published 2026

Polytherapy and Potential Drug–Drug Interactions in Geriatric Patients of a Tertiary-care Hospital

Shivangi Shukla, Jiya Thosar, Supriya Malhotra [...]

Apollo Medicine

Restricted accessResearch articleFirst published January, 2015

The Wider Use of Fixed-Dose Combinations Emphasizes the Need for a Global Approach to Regulatory Guideline Development

Yvonne Gautam, Ole J. Bjerrum, Merete Schmiegelow

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published July, 2015

An Analysis of the Fixed-Dose Combinations Authorized by the European Union,2009-2014

Dominik Sawicki-Wrzask, Mikael Thomsen, Ole J. Bjerrum

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 2017

Analysis of Fixed-Dose Combination Products Approved by the US Food and Drug Administration,2010-2015

Kyu Chan Kwon, Chulung Lee

Therapeutic Innovation & Regulatory Science

Open accessResearch articleFirst published June, 2025

Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1

Sandy Van Hemelryck, Erika Van Landuyt, Sofie Deleu [...]

Antiviral Therapy

Restricted accessResearch articleFirst published 2019

Investigation of Approval Trends and Benefits of New Fixed-Dose Combination Drugs in Japan

Chikara Kikuchi, Mifuyu Ohno, Takafumi Izumo [...]

Therapeutic Innovation & Regulatory Science

Restricted accessCase reportFirst published January, 2013

Inadequate Therapeutic Response to a Recommended Antituberculosis Fixed-Dose Combination Regimen in an Overweight Patient with Mycobacterium bovis Infection

Célia Lloret-Linares, Stéphane Mouly, Dan-Tranh Hoang-Nguyen [...]

Annals of Pharmacotherapy

Free accessResearch articleFirst published July, 2015

A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents

Heather Sevinsky, Xiaolu Tao, Reena Wang [...]

Antiviral Therapy

Open accessReview articleFirst published 2018

Sofosbuvir,velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

Marc Bourlière, Olivia Pietri, Paul Castellani [...]

Therapeutic Advances in Gastroenterology